Astellas Pharma Inc. Terminates Agreement On Acute Heart Failure Agent Carperitide

TOKYO, Jan 11, 2007 - Astellas Pharma Inc. (headquarters: Tokyo, president and CEO: Masafumi Nogimori, hereinafter “Astellas”) today announced that its US affiliate, Astellas US LLC, has terminated its license agreement with Daiichi Asubio Pharma Co., Ltd. (headquarters: Tokyo, president and CEO: Seiichi Yokoyama, hereinafter “Daiichi Asubio Pharma”) regarding North American and European Union rights to carperitide for the treatment of acute heart failure.